ReviewThe review of diabetic studies : RDS2012
Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome.
Review in The review of diabetic studies : RDS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03063229 (Energy Balance Following Islet Transplantation), which is not on this map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Energy Balance Following Islet Transplantation
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.Ontario health technology assessment series · 2015Pooled it
- Open Randomized Multicenter Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation.Transplantation · 2019Trial
- Trial
- Regenerative macrophages enhance stem cell-derived β cell function and engraftment.Science advances · 2026Article
- NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in mice.Cell death & disease · 2026Article
- Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.Biomedical microdevices · 2026Article
- Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling Improves Aab Measurement and Detection.Research square · 2026Article
- "Islet-on-a-Chip": A Microfluidic System Design for Preservation of Viability and Function of Human Islets of Langerhans - A Systematic Review.Visceral medicine · 2026Article
- Modulating immune response for the prevention and treatment of type 1 diabetes.Frontiers in immunology · 2026Review
- Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells.Disease models & mechanisms · 2026Article
- Increased production of humoral factor and PD-L1 expression induced by cytokine stimulation play a key role in the immunosuppressive effects of stem cells derived from human exfoliated deciduous teeth.Biochemistry and biophysics reports · 2025Article
- Characterization of diffusivity and mechanical properties of polyethylene glycol hydrogel conformal coatings over time for application in beta cell replacement therapy for type 1 diabetes.Cellular and molecular bioengineering · 2025Article
- Tracking Insulin- and Glucagon-Expressing Cells In Vitro and In Vivo Using a Double-Reporter Human Embryonic Stem Cell Line.Diabetes · 2025Article
- Identifying and optimizing critical process parameters for large-scale manufacturing of iPSC derived insulin-producing β-cells.Stem cell research & therapy · 2024Article
- Drug Integrating Amphiphilic Nano-Assemblies: 2. Spatiotemporal Distribution within Inflammation Sites.Pharmaceutics · 2024Article
- Pancreatic islet transplantation: current advances and challenges.Frontiers in immunology · 2024Review
- Unlocking the post-transplant microenvironment for successful islet function and survival.Frontiers in endocrinology · 2023Review
- Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment.Cell proliferation · 2022Review
- Effects of different routes of heparin on instant blood-mediated inflammatory reaction after portal vein islet transplantation.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?Frontiers in immunology · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remarkable progress has been made in islet transplantation over a span of 40 years. Once just an experimental curiosity in mice, this therapy has moved forward, and can now provide robust therapy for highly selected patients with type 1 diabetes (T1D), refractory to stabilization by other means. This progress could not have occurred without extensive dynamic international collaboration. Currently, 1,085 patients have undergone islet transplantation at 40 international sites since the Edmonton Protocol was reported in 2000 (752 allografts, 333 autografts), according to the Collaborative Islet Transplant Registry. The long-term results of islet transplantation in selected centers now match registry data of pancreas-alone transplantation, with 6 sites reporting five-year insulin independence rates ≥50%. Islet transplantation has been criticized for the use of multiple donor pancreas organs, but progress has also occurred in single-donor success, with 10 sites reporting increased single-donor engraftment. The next wave of innovative clinical trial interventions will address instant blood-mediated inflammatory reaction (IBMIR), apoptosis, and inflammation, and will translate into further marked improvements in single-donor success. Effective control of auto- and alloimmunity is the key to long-term islet function, and high-resolution cellular and antibody-based assays will add considerable precision to this process. Advances in immunosuppression, with new antibody-based targeting of costimulatory blockade and other T-B cellular signaling, will have further profound impact on the safety record of immunotherapy. Clinical trials will move forward shortly to test out new human stem cell derived islets, and in parallel trials will move forward, testing pig islets for compatibility in patients. Induction of immunological tolerance to self-islet antigens and to allografts is a difficult challenge, but potentially within our grasp.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.